microRepair ABX mousse versus 0.20% chlorhexidine for healing after tooth extraction
Evaluation of Healing in Post-Extraction Sockets Using microRepair Abx Mousse Mouthwash Versus 0.20% Chlorhexidine
This trial will test whether a biomimetic microRepair ABX mousse or a 0.20% chlorhexidine mouthwash helps adults 18–75 heal faster and with less pain after tooth extraction for endodontic or periodontal problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University of Roma La Sapienza Academic / other |
| Locations | 1 site (Roma, RM) |
| Trial ID | NCT07555366 on ClinicalTrials.gov |
What this trial studies
Adults scheduled for tooth extraction because of endodontic or periodontal issues are randomized to receive either a microRepair ABX mousse applied at home or a 0.20% chlorhexidine mouthwash. Clinical assessments occur at baseline and at 24 hours, 7 days, and 15 days post‑extraction, recording pain, swelling, odor, pigmentation, and plaque on the surgical wound. Wound healing is quantified using the Clinical Healing Index that assesses redness, edema, bleeding, suppuration, granulation tissue, epithelialization, and pain on palpation, while patient-reported outcomes include VAS pain scores and OHIP-14. The study also records patient satisfaction and product pleasantness and monitors adverse events during home application.
Who should consider this trial
Good fit: Adults aged 18–75 who require tooth extraction for destructive caries, untreatable endodontic or periapical lesions, advanced periodontal disease, traumatic root fractures, malpositioned teeth, or non-restorable residual roots.
Not a fit: Patients who are under 18 or over 75, pregnant or breastfeeding, immunocompromised, have severe psychiatric disorders, substance abuse, or smoke more than 10 cigarettes per day are excluded and would not be expected to receive benefit from this protocol.
Why it matters
Potential benefit: If successful, the microRepair ABX mousse could speed tissue regeneration and reduce post‑operative pain and complications compared with standard chlorhexidine.
How similar studies have performed: Chlorhexidine is an established standard for reducing oral microbial load and preventing complications, while biomimetic microparticle products like microRepair ABX have limited clinical evidence for post‑extraction wound regeneration and remain relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Age range: Patients between 18 and 75 years of age. Indication for tooth extraction: Specifically for cases involving: * Destructive caries that do not allow for conservative or prosthetic recovery. * Untreatable endodontic and/or periapical lesions. * Advanced periodontal lesions with significant loss of supporting tissue. * Traumatic lesions involving root fractures (vertical or at the middle third). * Malpositioned teeth causing functional alterations. * Roots that cannot be prosthetically recovered or residual roots. Exclusion Criteria: Age: Patients under 18 or over 75 years of age. Systemic Conditions: Presence of immunodepression or immunocompromisation (e.g., HIV infection). Pregnancy and Lactation: Women who are currently pregnant or breastfeeding. Mental Health: Presence of psychiatric disorders. Tobacco Use: Severe smokers, defined as consuming more than 10 cigarettes per day. Substance Abuse: History of alcohol or drug abuse.
Where this trial is running
Roma, RM
- Sapienza università di Roma — Roma, Rm, Italy (Recruiting)
Study contacts
- Study coordinator: Fabrizio Guerra
- Email: fabrizio.guerra@uniroma1.it
- Phone: 3283150627
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.